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The field of osteoimmunology has emerged in response to the range of evidences demonstrating the close interrelationship between
the immune system and bone metabolism. This is pertinent to immune-mediated diseases, such as rheumatoid arthritis and
periodontal disease, where there are chronic inflammation and local bone erosion. Periprosthetic osteolysis is another example
of chronic inflammation with associated osteolysis. This may also involve immune mediation when occurring in a patient with
rheumatoid arthritis (RA). Similarities in the regulation and mechanisms of bone loss are likely to be related to the inflammatory
cytokines expressed in these diseases. This review highlights the role of immune-related factors influencing bone loss particularly
in diseases of chronic inflammation where there is associated localized bone loss. The importance of the balance of the RANKL-
RANK-OPG axis is discussed as well as the more recently appreciated role that receptors and adaptor proteins involved in the
immunoreceptor tyrosine-based activation motif (ITAM) signaling pathway play. Although animal models are briefly discussed,
the focus of this review is on the expression of ITAM associated molecules in relation to inflammation induced localized bone loss
in RA, chronic periodontitis, and periprosthetic osteolysis, with an emphasis on the soluble andmembrane bound factor osteoclast-
associated receptor (OSCAR).
1. Introduction
The term osteoimmunology and the study of osteoimmunol-
ogy have developed due to the close interrelationship between
the immune system and bone metabolism [1]. This is evident
in immune-mediated diseases, such as rheumatoid arthritis
and periodontal disease (periodontitis), where there are local
bone erosion and inflammation as reviewed in detail in
multiple publications [2–4]. Similarities in the mechanisms
of bone loss in disease are likely related to the inflammatory
cytokines expressed in a number of bone loss diseases. These
cytokines are known to upregulate osteoclast activity via
increased expression levels of receptor activator NF kappa
B ligand (RANKL) relative to osteoprotegerin (OPG) (as
explored below) and increase localized bone loss in diseases
such as RA, periodontal disease, and periprosthetic osteolysis
[5–10].
This review highlights the role of immune-related cells
and factors in modulating bone loss, particularly in these
diseases. While the importance of the RANKL-RANK-OPG
axis has been appreciated for nearly two decades [11–13],more
recent studies have highlighted the importance of factors
associated with immunoreceptor tyrosine-based activation
motif (ITAM) signalling. This review will briefly discuss
the RANKL-RANK-OPG axis but its major focus will be
on the role of ITAM-associated factors, the more recently
investigated pathway, and how it relates to inflammatory bone
loss diseases, in particular osteoclast-associated receptor
(OSCAR) [14].
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2. Chronic Inflammation-Mediated Bone Loss
2.1. Rheumatoid Arthritis. Rheumatoid arthritis (RA) affects
1-2% of the population and involves an autoimmune reaction
with an autoantibody response to citrullinated proteins (and
others such as rheumatoid factor and collagen type II) [15].
RA is characterized by synovitis involving angiogenesis,
synovial proliferation, increased infiltration, survival, and
decreased apoptosis of inflammatory cells [16]. Further to this
there is an increase in osteoclast number and activity leading
to focal bone erosions, juxta-articular osteopenia, and joint
destruction [17–20]. Animal models suggest that there may
also be suppression of localised osteoblast formation of bone
[21].
2.2. Periodontitis and Similarities to RA. Periodontitis is a
chronic inflammatory disease of the gingival tissues, with
an associated loss of the supporting structures including
the periodontal ligament and alveolar bone. The aetiology
involves an inflammatory response to bacterial infection
such as P. gingivalis and possibly an autoimmune reaction,
as reviewed [22]. Periodontitis is the most common and
widespread bone loss pathology in humans with 64% of
the US population aged 65 years and older reported as
having moderate or severe periodontitis [23]. Despite the
prevalence of this disease the most common treatment is
either mechanical subgingival plaque removal or surgical
debridement. Inevitably, in the absence of effective treatment,
support structures (periodontium) are compromised and the
affected teeth will loosen and fall out.
RA and periodontitis have a similar pathophysiology,
characterized by destructive inflammation that culminates
in localized bone loss. The citrullination of proteins by P.
gingivalis and the subsequent generation of autoantigens that
drive autoimmunity in RA have been proposed as a possible
mechanism linking these two diseases [24]. Similarities in RA
and periodontitis may relate to citrullinated enolase as the
specific antigen involved aswell as cross-reaction between the
antibodies directed towards the immunodominant epitope of
human citrullinated alpha-enolase and a conserved sequence
on citrullinated P. gingivalis enolase [25].
New evidence suggests a relationship between the extent
and severity of chronic periodontitis and RA [24, 25].
Individuals with advanced RA are more likely to experience
more significant periodontal problems compared to their
non-RA counterparts and vice versa. This is supported by
findings in a study using a combined animalmodel of RA and
periodontitis [26], which demonstratedmore severe develop-
ment of arthritis in mice with periodontitis. Further to this,
mice in which periodontitis alone was induced had evidence
of radiocarpal bone loss in the absence of arthritic disease
[26]. Additionally, mice in which inflammatory arthritis was
induced also had evidence of periodontitis [26].This suggests
presence of either RA or periodontitis places the individual
at risk of developing the other disease. Both conditions
involve an imbalance between proinflammatory and anti-
inflammatory cytokines and increased bone-resorbing activ-
ity. Cantley et al. (2011) thus proposed that these two diseases
are related through a common underlying dysfunction of
fundamental inflammatorymechanisms [26]. New treatment
strategies are needed for both diseases that target the inhi-
bition of proinflammatory cytokines, destructive enzymes,
and bone-resorbing activity. The clinical implications of
the current research strongly suggest that patients with RA
should be carefully screened for their periodontal status, as
reviewed [27].
2.3. Peri-Prosthetic Osteolysis. Joint replacement surgery is
used as a last resort in osteoarthritis (OA) and RA patients
and is a relatively successful operation; however, a large
proportion of implants fail within 10–20 years as a result of
bone loss and implant loosening [4, 10, 28].The pathogenesis
behind prosthetic implant failure involves wear of prosthetic
alloys, such as polyethylene (PE), cobalt chrome, and tita-
nium liberated from the implant surface [29–31]. These par-
ticles stimulate a chronic inflammatory response [29], which
increases bone-resorbing activity of the osteoclasts [32] and
suppresses bone formation by the osteoblast [33, 34] resulting
in bone loss [25]. Periprosthetic tissues contain granuloma-
tous lesions dominated by inflammatory cells, particularly
macrophages, and foreign-body giant cells [29–31, 35, 36]. It is
believed that an inflammatory reaction is initiated within the
tissues in an attempt at particle clearance. This then becomes
a chronic reaction resulting in a granulomatous lesion. This
granulomatous lesion in periprosthetic osteolysis often leads
to the formation of pseudosynovium-like structure, in which
cells are organized into lining layer, in the membranous
tissues adjacent to the failed implant surface [35]. Juxtaposed
to this pseudosynovium are fibrous and collagenous regions,
possibly scar tissues, which could be indicative of late stage
periprosthetic osteolysis. The plethora of factors release in
this inflammatory reaction within the tissues contributes
towards the promotion of osteoclast formation [9, 37].
Higher numbers of T lymphocytes have been observed
in the periprosthetic tissues of human and mouse models
containing polyethylene and metal particles compared with
normal tissues [38–40] and osteoarthritic tissues [41]. Sandhu
et al. (1998) proposed that T cells are indirectly affected by
the inflammatory cascade induced by wear particles [40]. It is
however important to note that T cells make up less than 10%
of total cell population [42] in periprosthetic tissues. Given
the low levels of T lymphocytes, the general belief held is
that lymphocyte infiltrates are not normally associated with
wear-particle induced periprosthetic osteolysis, in particular,
in the granulomatous region [29, 32, 42, 43].The role of T cells
may however bemore pertinent in RApatients with implants.
The prevalence of foreign-body giant cells in response to
implant-derived wear debris in RA patients and non-RA
patients does not differ but appears to be linked to the amount
of polyethylene wear debris [36]. As would be expected,
this study reported a high prevalence of plasma cells in
lymphocytic infiltrates in untreated RA patients compared
with non-RA patients with a different distribution [36].
Whether implant wear is inducing a different reaction in RA
versus non-RA patients may potentially have implications for
combination and immune targeted treatment of inflamma-
tion and osteolysis in these patients.
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3. RANKL-RANK-OPG Axis
Receptor activator NF kappa B ligand- (RANKL-) RANK
signalling has several important roles in the immune system
and bone [13, 44–46]. Physiologically, RANKL is required
for normal development of lymph nodes [13], as evident in
knockoutmice. In bone, RANKL interactionwith its receptor,
RANK, expressed by the osteoclast, induces the transcription
factor nuclear factor of activated T cells-1 (NFATc1) [47–
49]. NFATc1 is an essential factor for differentiation, multi-
nucleation and activation [47–49]. NFATc1 binds directly to
and regulates osteoclast differentiation genes such as tartrate
resistant acid phosphatase (TRAP) [50], cathepsin K (Cath
K) [51], osteoclast-associated receptor (OSCAR) [52], 𝛽3-
integrin [53, 54], and calcitonin receptor (CTR) [50]. NFATc1
is also involved in autoregulation of itself, further enhancing
gene expression and osteoclast differentiation [55].
RANK-RANKL interaction is inhibited by the decoy
receptor OPG [12] and thus the ratio of RANKL to OPG
has a crucial influence on bone resorption [56]. Interactions
between RANK expressing cells of the lamina propria and
T cells expressing RANKL also play a role in intestinal
inflammation [57]. In the vasculature, RANKL interacts
with RANK to promote survival of endothelial cells [58].
Additionally, RANKL is upregulated in the keratinocytes of
inflamed skin [59]. Further to this, in an inflammatory arthri-
tismodel reminiscent of RA, activated T cells exacerbate joint
destruction via RANKL upregulation [46].
3.1. RANKL-RANK-OPG in Bone Pathologies. The RANK-
RANKL-OPG axis is known to regulate not only normal
bone physiology but also alterations in RANK-RANKL-OPG
interactions that play a role in bone disease. Uncoupling in
the balance between the level and activity of these molecules
culminates in osteoporotic or osteopetrotic phenotypes due
to an increase or decrease in osteoclast formation and activity.
This is particularly evident in focal bone loss associated
with chronic inflammatory diseases such as rheumatoid
arthritis, periodontal disease, and periprosthetic bone loss.
In active RA, periodontal disease, and prosthetic loosening,
elevated levels of RANKL relative to OPG are observed in
the synovial-like soft tissue, gingival tissue, and soft tissues
adjacent to sites of osteolysis [5–10]. Further to this the
elevated ratio of RANKL :OPG expression is associated with
increased differentiation and activity of the bone-resorbing
osteoclasts [5, 7–9, 32, 60], suggesting RANKL :OPG ratio as
an important indicator for bone erosion.
As RANKL and OPG are key molecules regulating bone
loss in diseases, therapeutic interventions targeting these
molecules and their signaling cascades are being investigated
to treat a wide range of diseases.
3.2. RANKL-RANK-OPG in RA. Osteoclasts are the promi-
nent cell eroding bone in inflammatory arthritis [20]. A
seminal paper in the field of osteoimmunology used a
RANKL knockout background to demonstrate that animals
developed an osteopetrotic phenotype and a reduction in
bone erosion, characterized by the absence of osteoclasts,
whilst inflammation did not differ between wild-type and
RANKL knockout mice [61]. In contrast, cartilage erosion
was present in both control littermate and RANKL knockout
mice [61], suggesting that the RANK-RANKL-OPG axis does
not directly affect cartilage metabolism.
In human studies, the levels of soluble RANKL have been
found to be higher than OPG in synovial fluids from patients
with RA compared with osteoarthritis (OA) patients [62]
suggesting a role in increased bone resorption. In support
of this, a more recent large center study has reported the
ratio of RANKL :OPG and markers of bone and cartilage
degradation (such as collagen terminal 1 (CTX-1)) to be
predictive of progression of radiological bone damage in RA
[60].
In synovial tissues from patients with active RA, RANKL
expression is predominantly located in sublining regions [62,
63] concentrated at focal sites of osteoclastic bone erosion in
the pannus- bone interface [64]. In contrast, OPG has been
described as being in regions of synovium some distance
from the sites of bone erosion in RA [64]. We reported
OPG is associated with endothelial cells and macrophages
in the synovial lining layer of OA and normal tissues whilst
absent in patients with active RA [63]. RANKL expressing
cells have been detected in a subset of fibroblast-like syn-
oviocytes and infiltrating mononuclear cells [62]. Further to
this, activated synoviocytes from RA tissue express RANKL
and have decreased OPG and are capable of supporting
osteoclastogenesis in vitro [65]. RANKL expressing cells are
also seen within areas of lymphocyte infiltration and dual
immunostaining by ourselves, and others have shown that
many of the RANKL-positive cells are a subset of CD3+ and
CD4+ cells [6, 62, 63]. ActivatedT cells fromRApatients have
increased RANKL are able to induce osteoclast formation in
vitro [62]. This study also reported a higher ratio of soluble
RANKL relative to OPG suggesting T cells as a source of
soluble RANKL in RA [62].
NFATc1 is a transcription factor crucial to RANKL-
RANK signaling in the osteoclasts [47] and is initially identi-
fied as being expressed by T cells and involved in regulation
of cytokine transcription [66]. We observed NFATc1 positive
cells in lymphocyte aggregates in RA tissues [67]. Many
of the NFATc1-immunostained mononuclear cells observed
were single nucleated and thus could be either precursor cells
of osteoclasts such as macrophages, or lymphocytes. Those
with lymphocyte morphology are most likely activated T
cells as most of them demonstrated NFATc1 positive staining
localized mainly in nucleus [67]. These cells may promote
osteoclastogenesis through the RANK/RANKL pathway [39]
because as already mentioned, as activated T-cells demon-
strate elevated expression of membrane-bound RANKL with
the ability to support osteoclastogenesis in vitro [62].
3.3. RANKL-RANK-OPG in Periodontal Disease. The relative
ratio of RANKL to OPG is also a significant indicator in
bone loss associated with periodontal disease [5, 69]. Soluble
RANKL is significantly higher in gingival crevicular fluid
(GCF) of periodontitis patients than in healthy GCF, while
OPG is not [69]. Similar to RA, B and T lymphocytes express
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RANKL in gingival tissues associated with periodontitis [5,
69] with expression of more than 50 and 90% of T cells
and B cells, respectively. Consistent with a role in osteoclast
regulation, lymphocytes isolated from gingival tissues of
patients induced differentiation of mature osteoclast cells
in a RANKL-dependent manner in vitro [69]. These results
suggest that activated T and B cells can be the cellular source
of RANKL and an inducer of bone resorption in periodontal
disease.
In a crude mRNA analysis of tissue from dental
patients, those with periodontitis exhibited significantly
higher NFATc1 gene expression, compared with healthy sub-
jects. Interestingly, NFATc1 and RANKL expression levels
strongly correlated with each other and with clinical peri-
odontal parameters [70].
3.4. RANK-RANKL-OPG in Peri-Prosthetic Osteolysis. Asep-
tic bone loss adjacent to orthopedic joint implants is a
common cause of joint implant failure in humans. RANK,
RANKL, and tumour necrosis factor (TNF-𝛼) are key mod-
ulators of bone turnover and their expression has been
reported by ourselves and others in the tissues near peripros-
thetic osteolysis in patients undergoing revision of total hip
prostheses [9, 71, 72]. These factors were strongly expressed
by large multinucleated cells containing polyethylene wear
debris in revision tissues [9]. More interestingly a strong
statistical correlationwas found between volume of bone loss,
polyethylene wear debris, and RANK, RANKL, and TNF-𝛼
expression [9].This was consistent with the earlier findings of
Stea et al. (2000) [72] where immunohistochemical detection
of TNF-𝛼 positively correlated with radiographic scores of
osteolysis.
In periprosthetic osteolysis, elevated levels of RANKL,
relative to its competitor OPG, are associated with increased
differentiation and activity of the bone-resorbing osteoclasts
[8, 32, 73]. An earlier study had shown that cells isolated from
periprosthetic tissues containing wear particles expressed
mRNA encoding for the proosteoclastogenic molecules,
RANKL, its receptor RANK, monocyte colony-stimulating
factor (M-CSF), interleukin- (IL-) 1 beta, TNF-𝛼, IL-6, and
soluble IL-6 receptor, as well as OPG [8]. Other studies
showed that osteoclasts formed from cells isolated from
periprosthetic tissues in the presence and absence of human
osteoblastic cells in vitro [8, 74]. When osteoclasts formed
in the absence of osteoblastic cells, markedly higher levels of
RANKL mRNA relative to OPG mRNA were expressed. Par-
ticles of prosthetic materials also stimulated human mono-
cytes to express both osteoclast-associated genes and osteo-
clastmediating factors in vitro [8].These findings suggest that
ingestion of prosthetic wear particles by macrophages results
in expression of osteoclast-differentiating molecules and
stimulation of macrophage differentiation into osteoclasts
[8]. Subsequent immunohistochemical studies demonstrate
significantly higher levels of RANKL in the periprosthetic
tissues of patients with implant failure than in similar tissues
from osteoarthritic and healthy subjects [32]. In contrast,
OPG protein levels were similar in all tissues with the net
result of higher RANKL :OPG ratio [32]. Of interest, RANKL
protein and mRNA were predominantly associated with
macrophage cells containing wear particles in the peripros-
thetic tissues [32].These findings support the contention that
high levels of RANKL in periprosthetic tissues of patients
with prosthetic loosening may significantly contribute to
aseptic implant loosening [32].
We observed both mRNA and protein expressions of
NFATc1 to be higher in periprosthetic osteolysis than in OA
tissues although levels did not reach significance [75]. This
is consistent with low T lymphocyte numbers observed in
these tissues. This may provide an explanation why lower
than expected NFATc1 protein and mRNA levels are found
in periprosthetic osteolytic tissues.
4. The ITAM Pathway in Osteoimmunology
The ITAM pathway regulates proliferation, survival, and dif-
ferentiation of effector immune cells and provides osteoclasts
with costimulatory signals [14, 76–80]. In preosteoclasts and
osteoclasts, innate immune receptors, TREM2 and OSCAR,
associate with the ITAM adaptor proteins DAP12 and Fc
receptor gamma-chain (FcR𝛾), respectively [80, 81]. DAP12
and TREM2 are required for differentiation into multinucle-
ated, bone-resorbing osteoclasts in vitro via phosphorylation
of the Syk tyrosine kinase [79]. OSCAR on the cell surface
mediates signal transduction via FcR𝛾 [82, 83] (Figure 1).The
induction of intracellular calcium via this pathway is required
in conjunction with RANKL-RANK interaction for NFATc1
induction [84].
4.1.Mutations of ITAM-AssociatedMolecules and Bone Pheno-
types In Vivo. In the context of human pathology the roles of
TREM2 or DAP12 have only begun to be recognized. Studies
in diseased tissues, particularly in Nasu-Hakola disease [85–
87] and very recently in Alzheimer’s disease [88], have shown
that these molecules may be involved. Mutations in TREM2
or DAP12 have been associated with bone pathologies such as
bone cysts and increased fractures (in addition to presenile
dementia) in Nasu-Hakola disease [87, 89]. These studies
support a role for DAP12 and a relationship between the
skeletal and psychotic characteristics observed in Nasu-
Hakola disease and for schizophrenia and presenile dementia
[90]. In TREM2 deficient individuals the osteoclast precur-
sors failed to differentiate into effective bone-resorbing cells
[91]. Consistent with this, Paloneva et al. [87] demonstrated
that function mutations in DAP12 and TREM2 result in an
inefficient and delayed differentiation of osteoclasts in vitro.
In postmenopausal osteoporosis a rare allele (G allele) of
OSCAR-2322A&gt; G (SNP in the 5󸀠 flanking region) has
been associated with lower bone mineral density [92].
Although animal models are not the focus of this review
it is interesting to note the phenotypes of ITAM related
molecules in single and combination knockouts. TREM−/−
mice have an osteopenic phenotype similar to Nasu-Hakola
disease. In vitro, lack of TREM2 impairs proliferation osteo-
clast precursors and affects the rate of osteoclastogenesis by
accelerating differentiation into mature osteoclasts [93] sug-
gesting different effects of knocking out TREM2 in vivo and





















Figure 1: RANGL-RANK-OPG axis and ITAM, the costimulatory pathway, in inflammation induced localised bone loss pathologies.
in vitro. In DAP12 deficient mice (−/−) there are an increased
bone mass (osteopetrosis) and impeded development of
osteoclasts. Mice that are double knockout for the adaptors
DAP12−/− and FcR𝛾−/− are severely osteopetrotic and bone
marrow derived osteoclast precursors from these mice are
unable to differentiate into mature osteoclasts in a RANKL-
andM-CSF-mediated culture system [79, 82]. Although there
is some redundancy, findings from these studies suggest that
DAP12 is the predominant factor responsible for optimal
osteoclast differentiation.
4.2. OSCAR Signalling and Function in Bone Regulation.
OSCAR is an IgG-like receptor expressed by monocytes,
macrophages monocyte-derived dendritic cells in humans,
and is involved in antigen presentation as well as survival,
maturation, and activation of dendritic cells [14, 76, 77, 83,
94, 95]. Ligation of human OSCAR on monocytes and neu-
trophils results in the induction of a proinflammatory cascade
and the initiation of downstream immune responses [95].
Importantly, cell bound OSCAR on osteoclast precursors is
an essential costimulatory factor in osteoclast formation but
does not bypass the requirement of RANKL. RANKL-RANK
induction of NFATc1 expression precedes that of OSCAR
[96] and is crucial for induction of OSCAR gene expression
[52]. In addition, ligand-activated OSCAR interacts with
FcR𝛾 to produce an increase in intracellular calcium [95]
that augments NFATc1 expression [96]. This establishes a
positive feedback loop that results in marked elevation of
both OSCAR and NFATc1 expressions in terminal stages of
osteoclast formation [52, 96]. These findings demonstrate a
significant role for OSCAR in immune modulation as well as
osteoclastogenesis.
In vitro studies demonstrate that addition of OSCAR-Fc
to osteoblast-osteoclast cocultures results in the inhibition of
osteoclast differentiation with Kim et al. (2002) suggesting
that this was due to OSCAR-Fc blocking an osteoblast
derived OSCAR ligand binding to OSCAR [14]. This may
be in addition to the recent identification of the motifs
within fibrillar collagens in the extracellular matrix (ECM)
as OSCAR ligands [97].The importance of OSCAR is further
highlighted by the fact that soluble OSCAR (s)OSCAR, in the
form of OSCAR-Fc, has also been shown to inhibit osteoclast
differentiation from PBMCs in the presence of RANKL, M-
CSF, and TGF-𝛽 [94].
Costimulatory immune pathways may further increase
osteoclast differentiation and activity [81, 82], particularly in
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chronic inflammatory diseases with an immune component
such as in RA, periprosthetic osteolysis, and periodontal
disease. In fact, our studies [67, 75] and those of others
suggest that deregulation of ITAM-associated molecules
contributes to the pathogenesis and severity of rheumatoid
arthritis, periodontal disease, periprosthetic osteolysis, and
osteoporosis [10, 67, 75, 92, 94, 98, 99].
4.3. Expression of ITAM-Associated Molecules in Chronic
Inflammation Induced Localised Osteolysis. We, and others,
have demonstrated increased levels of ITAM-related factors,
including TREM2, DAP12, OSCAR, and FcR𝛾 in human
periprosthetic tissues adjacent to sites of osteolysis [75]
and in RA synovial tissues [67, 94]. Additionally, we have
observed ITAM-related factors expressed in periodontitis
tissue adjacent to bone loss (unpublished observations). Of
these factors, soluble and membrane-bound OSCAR have
been more extensively assessed in the context of RA and
vascular disease (expanded on below).
4.4. Expression of ITAM-Associated Molecules in Rheumatoid
Arthritis. We observed markedly higher levels of TREM2,
DAP12, OSCAR, and FcR𝛾 in active RA patients com-
pared to synovial tissues from inactive RA, OA, or control
healthy joint. Multiple cell types expressed TREM2 including
mononuclear cells in lymphoid aggregates and fibroblasts
[67]. In OA tissues, TREM2 immunostaining was noticed in
monocyte/macrophage-like cells mainly around perivascular
areas and on blood vessels (unpublished observations). The
positive TREM2 immunostaining on the vasculature was
consistent with the finding on expression of TREM2 in
endothelial cells that has been documented earlier [100].
TREM2 immunostaining was also occasionally spotted on
lymphocyte-like cells in some OA tissues; however, to date
there has been no study indicating the expression of TREM2
in lymphocytes but further investigation is needed for confir-
mation.
Interestingly, DAP12 appeared predominantly associated
with macrophage-like cells in the sublining of the synovial
tissue, particularly in the macrophage-like cells in the lining
of the OA group [67]. More recently, a study by Chen et
al. (2014) [101] reported that mRNA expression levels of
DAP12 in the peripheral blood mononuclear cells of active
RA patients were significantly higher in active RA patients
than in inactive RAorOApatients.This is consistent with our
observations [67] of higher levels of DAP12 protein expressed
in the synovium in active RA patients than in inactive RA
or OA patients. They also noted that the levels significantly
decreased after effective therapy [101].
FcR𝛾 protein associates with fibroblasts and monocytes
of the synovial sublining whilst lymphoid aggregates and the
vasculature do not express FcR𝛾 [67]. Of note, similar to
DAP12, FcR𝛾 was associated with macrophage-like synovio-
cytes in the synovial lining with some scattered monocytes
in the sublining of the OA tissue. This increased DAP12 and
FcR𝛾 expression might indicate a role in the pathogenesis of
OA but this is yet to be determined [67].
4.5. Soluble and Synovial Tissue Levels of OSCAR in RA.
Analysis of human synovial tissue, serum, plasma, and
synovial fluid suggests that OSCAR expression is associated
with disease activity in RA [67, 94, 98, 99]. Recent studies
show that OSCAR protein expression is increased in mono-
cytes from RA patients compared with healthy individuals,
correlating with inflammatory disease activity (DAS28) [94].
OSCAR has also been noted to be expressed by mononuclear
cells adjacent to synovial microvessels in RA tissues [94].
Consistent with these findings, our immunohistochemical
studies show that high levels of OSCAR are associated with
mono- and multinuclear cells in active RA tissues compared
to tissues from OA and normal patients [67] (Figure 2).
Furthermore, semiquantitative analysis confirmed that there
is a significant elevation of OSCAR (𝑃 < 0.05) in active RA
synovial tissues compared to osteoarthritis synovial tissues.
This increased expression of OSCAR in the synovial tissue
of active RA suggests OSCAR regulation by inflammatory
cytokines and supports a role for OSCAR in the pathogenesis
of RA.
A study investigating the clinical, radiological, and
synovial immunopathological responses following anti-
rheumatic treatment in RA proposed that high synovial
tissue vascularity predicted favorable clinical and radiological
responses to treatment [102]. Similar to this, we previously
reported the increased OPG staining associated with the
vasculature in synovial tissues retrieved from the patient
in remission, OA and normal compared with active RA
[63]. Furthermore, we have reported increased levels of
OPG associated with vasculature following treatment with
DMARDS [7].
More recently we have detected increased expression
of OSCAR protein associated with the microvasculature
of synovial tissue from all inactive and active RA patient
tissues (9/9) compared to none in the normal synovial tissue
group (0/9) [67]. Importantly, in diseased tissues OSCARwas
expressedmostly on the luminal side of themicrovasculature,
consistent with OSCAR expression by endothelial cells [67,
103]. Our findings suggest that OSCAR is associated with
the endothelial cells of the microvasculature and is either
produced by endothelial cells or secreted by other cells and
bound by the endothelial cells in inflammatory states. The
marked reduction in the OSCAR associated with endothelial
cells observed in OA and healthy synovial tissues compared
with active RA indicates an immune modulatory mechanism
[67], which may also signal back to the osteoclasts and
regulate bone resorption.
Following observations ofOSCAR associationwith blood
vessels the expression ofOSCARwas investigated in endothe-
lial cell lines in vitro. Our analysis on bone marrow-derived
endothelial cells (BMECs) challenged with IL-1𝛽 and TNF-
𝛼 in vitro demonstrated that the inflammatory cytokines
increased OSCAR expressed as both mRNA and secreted
and membrane-bound proteins [67]. Together with in vivo
observations on synovial tissues and serum levels these
studies suggest that inflammatory cytokines in RA regulate
cleavage or secretion of sOSCAR from preosteoclasts or the
microvasculature.
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(a) (b)
Figure 2: OSCAR positive cells (red) in synovial tissue. (a) OSCAR immunostaining in the lining cells of OA tissues. (b) Mononuclear
OSCAR positive cells as indicated by arrow. The magnification was 400x.
(a) (b) (c)
Figure 3: Expression of osteoclast and vascular-associated molecules in mildly inflamed gingival tissues. (a) TRAP (osteoclast marker), (b)
OSCAR C. Von Willebrand factor to identify the microvasculature. The magnification was 200x.
The regulation by inflammatory cytokines, such as TNF-
𝛼, of OSCAR messenger RNA expression has also been
observed in monocytes [94]. Interestingly, levels of OSCAR
were found to increase in serum from RA patients following
anti-TNF treatment [94]. Of note, these studies did not
investigate gene or the release of protein OSCAR by human
peripheral blood derived osteoclasts in response to TNF-𝛼 in
conjunction with RANKL.
4.6. Expression of ITAM-Associated Molecules in Periodontal
Disease. To our knowledge, very limited descriptive or func-
tional studies have investigated ITAM factors in periodontitis
and normal gingival tissues. An early study however reported
that isolated polymorphonuclear neutrophils from GCF of
adult periodontitis patients exhibited higher Fc alpha RI and
Fc gamma RI levels and lower Fc gamma RIIa and Fc gamma
RIIIb levels than peripheral blood polymorphonuclear neu-
trophils. They found that GCF derived polymorphonuclear
neutrophils had a reduced ability to phagocytose and kill
IgG1-opsonized P. gingivalis compared to peripheral blood
polymorphonuclear neutrophils [104].
Our recent unpublished observations have identified
OSCAR colocalizing with TRAP in cells in serial sections
of mildly inflamed gingival tissue (Figure 3). Of note, these
osteoclast markers are highly expressed in themultinucleated
cells on the bone. Similar to the previous observations
of expression of ITAM-associated molecules in active and
inactive RA patients OSCAR expression was also noted in the
microvasculature. Given the similarities in pathogenesis of
RA and periodontitis [27] it is worth investigating expression
of ITAM factors in periodontitis, gingivitis, and normal
gingival tissues.
4.7. Expression of ITAM-Associated Molecules in Peri-
Prosthetic Osteolysis. We have reported a marked increase
in the levels of TREM2 and DAP12, OSCAR, and FcR𝛾 in
tissues containing PE particles, compared with OA synovial
control tissue when assessed by a semiquantitative scoring
system [75]. Furthermore, the observed increased levels of
these proteins in peri-prosthetic tissues were consistent with
the finding that the corresponding mRNA levels were also
increased [75]. Of interest, PE-containing osteoclast-like
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Figure 4: Expression of ITAM-associated molecules in PE-containing tissues from sites of aseptic loosening due to osteolysis. (a) TREM2,
(b) DAP12, (c) OSCAR, and (d) FcR𝛾 immunostaining. The magnification was 400x.
cells in these tissues were associated with high levels of
TREM2 and OSCAR protein and their respective adaptor
molecules DAP12 and FcR𝛾 [75] (Figure 4). Consistent with
these in vivo observations, PE particles added to human
peripheral blood derived osteoclast cells in vitro upregulated
ITAM expression [75].
It is important to also understand the role synovial
fluid may play in modulating regulators of cartilage and
bone destruction in the joint. Andersson et al. (2007) found
that synovial fluid from patients with OA stimulated the
mRNA expression of OSCAR and NFATc1 in mouse calvarial
implants in vitro, while mRNA expressions of DAP12 and
FcR𝛾 were not affected by synovial fluid from either revision
or OA patient groups. The authors suggested that perhaps
OSCAR and NFATc1 mRNA might be regulated by soluble
factors that are present in OA synovial fluid. However,
expression of DAP12 and FcR𝛾 was not regulated in the same
way [105]. This is an area that could further be explored.
Considering that inflammation recruits osteoclast pre-
cursors and can induce the differentiation and activation
of osteoclasts the enhanced expression of ITAM-related
molecules in revision tissues could exacerbate bone loss in
this disease.
4.8. Potential Role for OSCAR in the Clinic. Previous studies
have demonstrated that soluble fusion (OSCAR-fc) protein,
comprising the extracellular domain ofOSCAR, could inhibit
osteoclastogenesis in murine preosteoclast/osteoblast cocul-
tures [14] and PBMCs cultured in the presence of RANKL,
M-CSF, and TGF-𝛽 [94]. In this situation sOSCAR could
compete with OSCAR ligand and reduce OSCAR signalling.
The ability of soluble sOSCAR in vitro to impede osteoclast
formation may prove useful in inhibiting osteoclast differen-
tiation and may thus prevent bone damage in diseases such
as RA.
There is conflicting data as to whether sOSCAR increases
in healthy individuals or it increases as a result of erosive
activity in RA. Soluble OSCAR has been detected in serum
and reported to be higher in healthy compared to RA patients
[94, 99]. Serum levels of sOSCAR were shown to inversely
correlate with erosion and disease activity [99]. A recent
study, however, reported higher levels of sOSCAR in the
plasma of RA patients rather than healthy individuals [98].
We have also detected sOSCAR in the synovial fluid of OA
and active RA patients with no significant difference between
these diseases [67].We believe that sOSCAR has the potential
to act as decoy receptor for OSCAR ligand within the joint
and affect osteoclast development in RA. It is possible that
successful treatment results in increased cleavage of cell
associated OSCAR resulting in increased sOSCAR levels in
the joint. In this way sOSCAR regulates osteoclastic bone
resorption and is an early marker that predicts joint damage.
The biological effect of serum and synovial fluid-derived
OSCAR on osteoclastogenesis is yet to be investigated.
Synovitis and erosion are not always linked with some
patients having progressive erosive disease despite being in
remission and it is unclear what factors drive this [106]. The
discordance between clinical inflammatory disease activity
and radiological outcomes emphasizes the need for a vali-
dated marker of bone damage in conjunction with current
clinical parameters that are routinely assessed [107, 108]. The
ability to monitor bone erosion will allow the clinician to
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make important decisions on therapy earlier [109] and reduce
structural joint damage [110]. Currently unaddressed RA-
induced joint damage affects mobility of patients later in life
and predisposes to secondary osteoarthritis [110]. In addition,
while we have numerous markers that reflect inflammation
and related disease activity there are none that monitor joint
erosion, other than X-rays which only indicate damage after
it has occurred [111]. Therefore, it is essential that an accurate
early marker of joint erosion is identified in order to guide
effective treatment modalities in order to protect the joint of
arthritic patients.
5. Conclusion
While the significance of ITAM-associated molecules has
been largely established in the context of bone biology and
an immunological point of view, limited studies have been
carried out on osteoclast ITAM-related molecules in human
bone pathologies. The increased levels of ITAM factors in
inflamed tissues adjacent to sites of localized bone loss in
RA, periodontal disease, and periprosthetic osteolysis may
prove indicative of the disease progression. Further to this,
levels of the soluble factor, OSCAR, in serum or local fluid,
may provide us with a potential bone destructive marker and
potential target for modulation of bone erosion.
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